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implantable device-based tool that collates data pertaining to heart
rhythm, heart rate, intrathoracic ﬂuid status, and activity, produc-
ing a risk score that correlates with 30-day risk of heart failure (HF)
hospitalization.
OBJECTIVE We sought to validate the ID algorithm using the
Resynchronization-Deﬁbrillation for Ambulatory Heart Failure Trial.
METHODS Diagnostic measures of the algorithm include OptiVol ﬂuid
index, nighttime heart rate, minutes of patient activity, heart rate
variability, and combined measure of cardiac rhythm and biventricular
pacing. Monthly evaluations of ID parameters were assessed for the
development of HF symptoms and hospitalization for HF.
RESULTS A total of 1224 patients were included: 741 (61%) with
cardiac resynchronization therapy with deﬁbrillator devices and 483
(39%) with implanted cardioverter-deﬁbrillator only. The mean age
was 66  9 years, and 1013 (83%) were men. A total of 37,861
months of follow-up data were available, with 258 HF hospitalizations
(event rate 0.68% per month). There were 33 HF hospitalizations
during low-risk months (0.21% per month), 123 during medium-risk
months (0.66% per month), and 102 during high-risk months (2.61%
per month). Compared with low-risk months, and 95% conﬁdence
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variable analysis demonstrated that each ID variable had independent
association with HF hospitalization.
CONCLUSION The risk of HF as determined by the ID algorithm
correlated with HF hospitalization and several HF signs and
symptoms among patients in the Resynchronization-Deﬁbrillation
for Ambulatory Heart Failure Trial. This may present a useful adjunct
to detect early signs of HF and adjust therapy to reduce morbidity
and costs involved with hospital admission.
KEYWORDS Heart failure; ICD; Diagnosis; Algorithm; Hospital
admission
ABBREVIATIONS ACT ¼ minutes of patient activity; CI ¼
conﬁdence interval; CRT ¼ cardiac resynchronization therapy;
CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator;
FI ¼ ﬂuid index; HF ¼ heart failure; HRV ¼ heart rate
variability; ICD ¼ implanted cardioverter-deﬁbrillator; ID ¼
integrated diagnostics; NHR ¼ nighttime heart rate; NYHA ¼
New York Heart Association; RAFT ¼ Resynchronization-
Deﬁbrillation for Ambulatory Heart Failure Trial
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Heart failure (HF) is an issue of signiﬁcant and increasing
burden to population health and health care resources.Approximately 5.1 million Americans suffer from HF with
more than 1 million hospitalizations on an annual basis and
an average readmission rate of 25% at 1 month.1 This incurs
a $40 billion cost to the health care system annually, with
over half of this cost due to hospital admissions. A number of
prediction tools have been developed in an attempt to
identify patients with HF at high risk of death.2,3 These tend
to require patient evaluation, tests, and laboratory results that
must be updated each time a patient’s risk is reassessed. The
integrated diagnostics (ID) algorithm is an implantable
device-based tool that collates data pertaining to heart
rhythm, heart rate, intrathoracic ﬂuid status, and activity,http://dx.doi.org/10.1016/j.hrthm.2014.05.015.
Figure 1 Schematic of the ID algorithm. Participants are assigned a value for each variable on a daily basis. These values are then combined with a risk score
that is categorized into low, medium, or high risk. HF ¼ heart failure; ID ¼ integrated diagnostics.
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HF hospitalization.4 It is a dynamic assessment tool in which
variables are continuously updated, and it is widely available
in existing implantable cardioverter-deﬁbrillator (ICD) and
cardiac resynchronization therapy (CRT) devices. The
cohorts initially used for derivation5–7 and validation8–10 of
the ID risk score were drawn from prospective nonrandom-
ized studies and included only patients with CRT-D (CRT
with deﬁbrillation capability) devices. We sought to further
validate the ID algorithm and test its association with HF
hospitalization as well as with the incidence of HF symptoms
in patients enrolled in the Resynchronization-Deﬁbrillation
for Ambulatory Heart Failure Trial (RAFT),11 a large
international clinical trial of patients with congestive HF
including both ICD and CRT-D devices.Methods
RAFT was a multicenter randomized controlled study in
patients with New York Heart Association (NYHA) class II
or III symptoms, left ventricular systolic dysfunction, and a
wide QRS complex. The rationale, design, inclusion/exclu-
sion criteria, and end points have been published previ-
ously.12 Brieﬂy, 1798 patients were enrolled and randomized
to ICD or CRT-D. The primary outcome was a composite
end point of death from any cause or hospitalization for HF.
Hospitalization for HF alone was a prespeciﬁed secondary
outcome and was deﬁned as admission to hospital for more
than 24 hours for treatment of HF. Patients with an implanted
device with the capability of monitoring and storing all
elements of the ID algorithm were included in this analysis.
Diagnostic measures of the ID algorithm include the
following 5 variables with measurement thresholds as deter-
mined by previous studies:8,13,14 (1) Intrathoracic impedance,
measured from the right ventricular coil to the pulse generator,
was used to compute the OptiVol ﬂuid index (FI), reﬂec-
ting volume status and lung congestion15 and stratiﬁed to
4 levels of worsening lung congestion: level 1: 0r FIo 30ohm-days; level 2: 30r FIo 60 ohm-days; level 3: 60r FI
o 100 ohm-days; level 4: FIZ100 ohm-days. (2) Nighttime
heart rate (NHR), the average heart rate between midnight and
4 AM, was stratiﬁed to 2 levels: level 1: NHR 55–85 beats/
min; level 2: NHR Z85 beats/min, r55 beats/min, or
increasing. (3) Number of minutes of patient activity (ACT)
per 24-hour period as detected by the device’s piezoelectric
sensor was stratiﬁed to 2 levels: level 1: ACT 460 min/d;
level 2: ACTr60 min/d or decreasing activity. (4) Heart rate
variability (HRV) was measured as the SD of 5-minute
medians of intervals over a 24-hour period and stratiﬁed to
2 levels: level 1: HRV standard deviation of normal intervals
(SDNN) 460 ms; level 2: HRV SDNN r60 ms or
decreasing HRV. (5) A combined measure of heart rhythm
included 4 factors measured over 24 hours: atrial ﬁbrillation
burdenZ1 h/d, mean ventricular rate during atrial ﬁbrillation
Z90 beats/min, a single shock for ventricular tachyarrhythmia
whether ventricular tachycardia or ventricular ﬁbrillation or 5
ventricular tachyarrhythmia episodes treated with antitachy-
cardia pacing in 24 hours, and percent pacing in patients with
a CRT device r90% (in whom 100% paced beats is
intended), and this combined measure was stratiﬁed to 2
levels: level 1: only 1 of 4 criteria met; level 2: 2 or more
criteria met. These 5 measures were then entered in a Bayesian
belief network16 to generate a summary HF risk score. The
risk score was categorized into low, medium, or high risk for
HF. A schematic of the ID algorithm is displayed in Figure 1.
Patients were seen for follow-up 1 month after device
implant and every 6 months, consisting of device interrogation,
full clinical assessment, and survey of health changes since the
last visit. Patients and the treating health team including
physicians were blinded to study arm assignment, while a
separate health care team including implanting and device
management physician was unblinded. All events were adju-
dicated by an independent, blinded end-point committee. The
study was coordinated and database maintained by the Car-
diovascular Research Methods Center at the University of
Ottawa Heart Institute. The Canadian Institutes of Health
Table 1 Baseline characteristics
n (%)
Characteristic
Patients
included
Patients not
included
Device type
CRT-D 741 (61) 138 (25)
ICD 483 (39) 423 (75)
Age (y), mean  SD 66  9 66  10
Sex: male 1013 (83) 477 (83)
NYHA functional class
II 1062 (87) 376 (66)
III 162 (13) 198 (34)
Ischemic 798 (65) 403 (70)
Renal dysfunction 213 (17) 144 (25)
Pulmonary 308 (25) 139 (24)
Hypertension 530 (43) 269 (47)
Diabetes 408 (33) 198 (34)
Chronic AF 133 (11) 76 (13)
VT/VF 226 (18) 121 (21)
LVEF (%), mean  SD 23  5 22  6
Baseline medications
ACE inhibitor 967 (79) 452 (79)
ARB 269 (22) 127 (22)
β-Blockers 1100 (90) 503 (88)
Diuretics 1005 (82) 508 (89)
Statins 847 (69) 378 (66)
Nitrates 329 (27) 186 (32)
Digoxin 393 (32) 201 (35)
Calcium-channel 137 (11) 47 (8)
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a peer-reviewed process, but did not participate in the conduct
of the trial, collection, or assessment of the parent trial data.
For the HF admission analysis, monthly evaluations of ID
parameters were simulated to occur every 30 days. For each
monthly evaluation, the maximum HF risk score was deter-
mined from the daily risk score for the previous 30 days. This
maximum HF risk score was used to categorize the monthly
evaluations into low (risk scoreo0.054), medium (risk score
0.054–0.20), and high (risk score Z0.20) risk. HF exacerba-
tion was evaluated in the 30 days after the monthly evaluation.
Monthly evaluations were included in the analysis if there were
30 days of diagnostic data available before the evaluation and
30 days of follow-up available after the monthly evaluation to
evaluate the risk of HF exacerbation. For the analysis of signs
and symptoms of HF, ﬁndings on follow-up visits were
assessed according to the highest ID risk score in the 30 days
preceding clinical assessment. Patients implanted with CRT-D
generators without left ventricular leads (n ¼ 155) were
included in the ICD-only device group. A generalized estimat-
ing equation model was used to estimate the relative risk along
with the 95% conﬁdence intervals (CIs) to account for the
multiple evaluations in each patient. An interaction term was
tested for all pairwise groupings of ID variables with regard to
HF admission. All statistical analyses were performed using
SAS version 9.2 (SAS Institute, Inc, Cary, NC).blocker
AAD 175 (14) 109 (19)
Anti-coag/platelet 1093 (89) 511 (89)
AAD ¼ antiarrhythmic drug; ACE ¼ angiotensin-converting enzyme;
AF¼ atrial ﬁbrillation; ARB¼ angiotensin receptor blocker; CRT-D¼ cardiac
resynchronization therapy with deﬁbrillator; ICD ¼ implanted cardioverter-
deﬁbrillator; LVEF ¼left ventricular fraction; NYHA ¼ New York Heart
Association; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.Results
The results of RAFT have been published previously.11
Brieﬂy, 1798 patients were enrolled at 34 centers between
2003 and 2009, with 40  20 months of follow-up. The
primary outcome, death from any cause or hospitalization for
HF, occurred in 364 of 904 patients (40.3%) in the ICD-only
group and 297 of 894 patients (33.2%) in the CRT-D group
(hazard ratio 0.75; 95% CI 0.64–0.87; Po .001). A total of
410 patients were admitted to the hospital with a diagnosis of
HF over the course of the trial, more commonly in the ICD
group (26.1%) than in the CRT-D group (19.5%) (hazard
ratio 0.68; 95% CI 0.56–0.83; P o .001).
Of all the study participants enrolled in RAFT, 1224
patients received devices capable of monitoring and storing
all 5 ID variables and were included in this analysis. The
mean age was 66  9 years, and 83% were men. Of these
patients, 741 received CRT-D devices and 483 only ICD.
Baseline characteristics are summarized in Table 1. Compar-
isons were made between these 1224 patients and the
574 patients who could not be included. Compared with
those excluded, patients included in this analysis more often
had a CRT-D device (61% vs 25%; Po .001), more NYHA
class II HF (as opposed to NYHA class III HF) (87% vs 66%;
Po .001), less ischemic etiology of HF (65% vs 70%; P ¼
.044), less renal dysfunction (17% vs 25%; P o .001), less
diuretic use (82% vs 89%; P¼ .001), less nitrate use (27% vs
32%; P ¼ .016), and less antiarrhythmic medication use
(14% vs 19%; P ¼ .011). Other baseline variables in Table 1
did not differ signiﬁcantly.Of the 1224 ID patients, 37,861 months of follow-up data
were available, with 258 hospitalizations for HF (event rate
0.68% per month). The ID algorithm assessed 41% of total
months as low risk, 49% as medium risk, and 10% as high risk.
There were 33 HF admissions during low-risk months (event
rate 0.21% per month), 123 during medium-risk months
(0.66% per month), and 102 during high-risk months (2.61%)
(Table 2). Compared with low-risk months, the relative risk of
HF admission during medium-risk months was 2.9 (2.0–4.4)
and during high-risk months it was 10.7 (6.9–16.6). The
cumulative risk of hospital admission is illustrated in Figure 2.
Patients in the ICD and CRT-D groups were assessed
separately. Details are presented in Table 3. The number of
low-, medium-, and high-risk months were similar between
the 2 groups. The overall incidence of HF hospitalization was
0.73% per month in patients with CRT-D and 0.60% in
patients with ICD only. The ID algorithm showed event rates
of 0.21% per month in patients with CRT-D and 0.22% per
month in patients with ICD, which were determined as low
risk; 0.74% in patients with CRT-D and 0.53% in patients
with ICD only, which were determined as medium risk; and
2.73% in patients with CRT-D and 2.40% in patients with
Table 2 ID-determined risk of HF exacerbation/admission
ID risk No. of months
Event rate
per month
Relative risk
(95% CI)
All (N ¼ 1224) 37,861 258 (0.68%)
Low 15,359 (41%) 33 (0.21%) Reference
Medium 18,595 (49%) 123 (0.66%) 2.9 (2.0–4.4)
High 3907 (10%) 102 (2.61%) 10.7 (6.9–16.6)
CI ¼ conﬁdence interval; ID ¼ integrated diagnostics.
Table 3 CRT-D vs ICD
Device No. of months
Event rate
per month
Relative risk
(95% CI)
CRT-D (n ¼ 758) 24,243 176 (0.73%)
Low risk 9,934 (41%) 21 (0.21%) 3.3 (2.0–5.4)
Medium risk 11,820 (49%) 87 (0.74%) 11.3 (6.5–19.7)
High risk 2,489 (10%) 68 (2.73%)
ICD (n ¼ 484) 13,618 82 (0.60%)
Low risk 5,425 (40%) 12 (0.22%) 2.3 (1.2–4.6)
Medium risk 6,775 (50%) 36 (0.53%) 9.6 (4.6–19.7)
High risk 1,418 (10%) 34 (2.40%)
CI ¼ conﬁdence interval; CRT-D ¼ cardiac resynchronization therapy
with deﬁbrillator; ICD ¼ implanted cardioverter-deﬁbrillator.
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risk of HF hospitalization in the medium-risk group (com-
pared with the low-risk group) was 3.3 (2.0–5.4) in patients
with CRT-D and 2.3 (1.2–4.6) in patients with ICD only, and
in the high-risk group it was 11.3 (6.5–19.7) in patients with
CRT-D and 9.6 (4.6–19.7) in patients with ICD only.
Patients with NYHA class II and III HF were assessed
separately. Details are presented in Table 4. Patients with
NYHA class III HF had a higher rate of HF hospitalization
than did patients with NYHA class II HF (1.16% per month vs
0.60% per month), and there were progressively increasing HF
hospitalization rates in both NYHA class II HF and NYHA
class III HF from low to medium to high risk as assigned by the
ID algorithm. The relative risk of HF hospitalization in the
medium-risk group (compared with the low-risk group) was
2.9 (1.8–4.5) in patients with NYHA class II HF and 3.0 (1.2–
7.3) in patients with NYHA class III HF, and in the high-risk
group it was 10.7 (6.4–17.8) in patients with NYHA class II
HF and 9.0 (3.8–21.6) in patients with NYHA class III HF.
Univariable analysis demonstrated a signiﬁcant associa-
tion of each of the 5 factors with HF hospitalization (see
Online Supplemental Table 1). In multivariable analysis,
each factor remained independently associated with HF
hospitalization (Table 5). Increasing thoracic impedance
was associated with a relative risk of hospitalization of 3.9
(2.6–5.9), combined heart rhythm 3.1 (1.6–6.0), activity
level 2.2 (1.5–3.1), HRV 1.7 (1.2–2.5), and NHR 1.6Figure 2 Incidence of hospitalization for heart
failure over 30 days in patients enrolled in RAFT
stratiﬁed according to ID-determined risk status.
ID ¼ integrated diagnostics; RAFT ¼ Resynchroni-
zation-Deﬁbrillation for Ambulatory Heart Failure
Trial.(1.2–2.3). There was no signiﬁcant interaction in any pair
of ID variables with regard to hospital admission.
The presence of individual signs and symptoms of HF at
follow-up visits was also assessed for correlation with ID-
determined risk. All signs and symptoms with the exception of
the presence of S3 or S4 had a signiﬁcantly higher incidence in
high risk than in low risk, and elevated jugular venous
pressure, orthopnea/paroxysmal nocturnal dyspnea, and
peripheral edema had a signiﬁcantly higher incidence in
medium risk than in low risk. Details are presented in Table 6.
Discussion
In RAFT, a trial of 1798 patients with HF, 23% of the patients
were hospitalized with HF over a mean follow-up period of 40
months. This is representative of the enormous, and increas-
ing, health care and economic burden presented by HF
exacerbation. Patients at highest risk typically have impaired
left ventricular function with HF symptoms. They therefore
have an indication for an ICD or CRT-D device,17–20 which
provides an ongoing means for the collection and analysis of
physiological parameters. In contrast to conventional risk
scores that are static by design, a risk score based on
Table 5 Multivariable analysis of ID factors
Factor Relative risk (95% CI) P
OptiVol
1 Reference o.001
2 1.5 (0.9–2.3)
3 2.5 (1.5–4.1)
4 3.9 (2.6–5.9)
Nighttime heart rate
1 Reference .004
2 1.6 (1.2–2.3)
Activity
1 Reference o.001
2 2.2 (1.5–3.1)
Heart rate variability
1 Reference .002
2 1.7 (1.2–2.5)
Combined heart rhythm
0 Reference .002
1 1.4 (0.8–2.5)
2 3.1 (1.6–6.0)
CI ¼ conﬁdence interval; ID ¼ integrated diagnostics.
Table 4 NYHA class II vs NYHA class III
NYHA class No. of months
Event rate
per month
Relative risk
(95% CI)
Class II (n ¼ 1062) 32,265 193 (0.60%)
Low risk 13,398 (42%) 26 (0.19%) 2.9 (1.8–4.5)
Medium risk 15,755 (49%) 92 (0.58%) 10.7 (6.4–17.8)
High risk 3,112 (10%) 75 (2.41%)
Class III (n ¼ 162) 5,596 65 (1.16%)
Low risk 1,961 (35%) 7 (0.36%) 3.0 (1.2–7.3)
Medium risk 2,840 (51%) 31 (1.09%) 9.0 (3.8–21.6)
High risk 795 (14%) 27 (3.40%)
CI ¼ conﬁdence interval; NYHA ¼ New York Heart Association.
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potentially detect high or increasing risk of HF exacerbation
before hospitalization is required and provide a timely signal
to physicians through remote monitoring. This may prevent
hospitalization by signaling the need for change to ongoing
therapy, thereby potentially reducing morbidity and costs.
The ID algorithm has been developed on the basis of the
testing of a number of physiological parameters, incorporating
those demonstrating strongest association with HF exacerba-
tion.4 The cohorts initially used to develop the risk score were
nonrandomized studies with 921 and 1310 patients for deriva-
tion and validation, respectively. The present study establishes
the algorithm in the context of a large, multicenter, randomized
clinical trial with 37,829 patient-months of follow-up data.
Patients enrolled in RAFT had signiﬁcant left ventricular
dysfunction and preexisting HF with at least a moderate risk
of exacerbation and hospital admission. The subset of patients
included in the present analysis had more biventricular pacing,
less renal dysfunction, and less use of diuretics, nitrates, and
antiarrhythmic medications than did the average study partic-
ipant. These differences reﬂect the fact that OptiVol-capable
devices were introduced midway through RAFT at a time when
enrollment criteria were altered to include only patients with
NYHA class II symptoms and no longer include patients with
NYHA class III symptoms. Therefore, patients with NYHA
class III symptoms, enrolled early in the trial, are under-
represented. The observed event rate may therefore be an
underrepresentation, biasing to some degree against the power
of the ID algorithm to estimate HF exacerbation risk.
The rate of HF hospitalization in patients enrolled in RAFT
was 0.68% per month, or 1 admission per 146 patient-months
of follow-up. This rate reﬂects a somewhat lower-risk
population than did the admission rate of the prior ID
validation set4 (0.93% per month, or 1 admission per 108
patient-months of follow-up). Patients who are determined
“low risk” by the algorithm had an HF hospitalization rate of
0.22% per month, those determined “medium risk” had a 2.9-
fold higher rate (0.66% per month), and those determined
“high risk” had a 10.7-fold higher rate (2.61% per month).
Approximately 10% of months were determined high risk and
50% medium risk. On a practical level, adjustment of therapy
in response to a high-risk determination would therefore be an
infrequent occurrence. Ten thousand high-risk determinations
in patients enrolled in RAFTwould be associated with 261 HFadmissions. If these admissions are preventable with change to
therapy, the number of high-risk determinations to prevent 1
hospitalization in patients enrolled in RAFT would be
approximately 38. On the basis of the observation that 10%
of ID assessments are high risk, 120 of the 1200 participants in
the present analysis would be high risk in a given month. In a
best-case scenario, if each of the 38 high-risk determinations
could potentially save 1 admission by therapy, then approx-
imately 3 HF admissions could be prevented per month.
Although this clearly requires a prospective cost-beneﬁt study
of ID-directed therapy, it suggests a potential for reduction in
morbidity and costs in spite of low incidence of HF admission.
The present study further establishes that each element of
the algorithm—thoracic impedance, NHR, physical activity,
heart rate variability, and the combined measure of arrhyth-
mia with CRT pacing—shows independent association with
HF admission. The strongest association was with high
thoracic impedance as measured by OptiVol (relative risk
3.9), followed by the combined heart rhythm counter
(relative risk 3.1). The latter incorporates a measure of
percent biventricular paced beats and may reﬂect, to some
degree, the effect of CRT on HF symptoms. Prior validation
of the ID algorithm has been in CRT-D devices only, and this
analysis extends the ﬁndings to non-CRT ICD patients.
Patients in the ICD arm had a similar rate of HF admission,
and Table 3 conﬁrms that the ID algorithm behaved similarly
in patients with ICD and patients with CRT-D in terms of
number of low-, medium-, and high-risk months assigned
and relative risks associated with these designations.
Study limitations
This study has some limitations that should be considered. The
ID algorithm is speciﬁc to Medtronic devices, and the results are
therefore limited to patients with these devices. Clinical signs
and symptoms of HF are important aspects of the diagnosis that
are not assessed by the device, and although the sensitivity and
speciﬁcity of the algorithm for speciﬁc clinical manifestations
Table 6 Association of symptoms with ID-determined risk
Events Relative risk (95% CI) (reference low) P (vs low risk)
Sign and symptom
Total
(n ¼ 5326)
Low risk
(n ¼ 2085)
Medium risk
(n ¼ 2630)
High risk
(n ¼ 611) Medium risk High risk Medium risk High risk
Elevated JVP 1778 (33%) 589 (28%) 894 (34%) 295 (48%) 1.3 (1.1–1.4) 1.9 (1.6–2.3) o.001 o.001
Rales 322 (6) 94 (5) 150 (6) 78 (13) 1.2 (0.9–1.5) 2.6 (1.9–3.7) .25 o.001
S3 or S4 present 660 (12) 246 (12) 318 (12) 96 (16) 1.0 (0.9–1.2) 1.3 (1.0–1.7) .90 .096
Orthopnea/PND 429 (8) 120 (6) 210 (8) 99 (16) 1.3 (1.0–1.6) 2.7 (2.0–3.6) .033 o.001
Peripheral edema 1119 (21) 322 (15) 580 (22) 217 (36) 1.4 (1.2–1.6) 2.2 (1.8–2.7) o.001 o.001
Sacral edema 67 (1.3) 11 (0.5) 31 (1.2) 25 (4.1) 1.8 (0.9–3.4) 5.9 (2.8–12.3) .074 o.001
Hepatomegaly 172 (3.2) 47 (2.3) 88 (3.3) 37 (6.1) 1.3 (0.9–1.9) 2.1 (1.3–3.3) .11 .003
Murmur 1173 (22) 394 (19) 585 (22) 194 (32) 1.1 (1.0–1.3) 1.5 (1.2–1.9) .039 o.001
Dyspnea on exertion 3068 (58) 1133 (54) 1518 (58) 417 (68) 1.1 (1.0–1.2) 1.5 (1.2–1.8) .12 o.001
Fatigue 2218 (42) 801 (38) 1080 (41) 337 (55) 1.0 (0.9–1.1) 1.5 (1.2–1.7) .598 o.001
ID ¼ integrated diagnostics; JVP ¼ jugular venous pressure; PND ¼ paroxysmal nocturnal dyspnea.
1631Gula et al Device Algorithm to Detect Heart Failureare presented in Table 6, the algorithm is not a substitute for
clinical assessment and decision making. We do not have data
on how many patients were hospitalized for HF when the ID
score was low, how many had a high ID score in the absence of
HF, or what costs are associated with these false-negative and
false-positive results. All these are essential next steps in
evaluating the algorithm and are currently underway.
Conclusion
The risk of HF as determined by a cardiac device-based
algorithm correlated with HF admission and with several HF
symptoms and signs among patients enrolled in RAFT. This
may present a useful adjunct to detect early signs of
congestive HF and adjust therapy to reduce morbidity and
costs involved with hospital admission.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrthm.
2014.05.015.References
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